Pityriasis Folliculorum: Response to Topical Ivermectin

Abstract

Pityriasis folliculorum has been described as a dry type of rosacea with extensive proliferation of Demodex folliculorum in pilosebaceous follicles of the skin. This skin condition is frequently difficult to manage, with various treatment options showing mixed efficacy. Oral ivermectin, a macrocyclic lactone parasiticide with anti-inflammatory and anti-parasitic effects, is one of the leading treatment modalities for demodicosis. Topical ivermectin has recently been FDA approved as therapy for rosacea. We present the case of a woman with pityriasis folliculorum who showed significant improvement from using topical ivermectin with no adverse events related to treatment.

• Authors: Kavita Darji, Nicole M Burkemper
• Journal: Journal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 16 Issue 12 Pg. 1290-1292 (12 01 2017) ISSN: 1545-9616 [Print] United States
• PMID: 29240866 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antiparasitic Agents
• Ivermectin

Topics

• Administration, Cutaneous
• Adult
• Antiparasitic Agents (administration & dosage, therapeutic use)
• Diagnosis, Differential
• Female
• Humans
• Ivermectin (administration & dosage, therapeutic use)
• Pityriasis (diagnosis, drug therapy, pathology)